Product Description
an orally active protease-activated receptor-1 antagonist that has recently completed Phase II clinical investigation. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22871190/)
Mechanisms of Action: PAR1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Inflammation|Coronary Artery Disease|Acute Coronary Syndrome|Myocardial Ischemia|Coronary Disease
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| E5555-A001-023 | P1 |
Completed |
Healthy Volunteers |
2011-08-01 |
|
| E5555-A001-022 | P1 |
Completed |
Healthy Volunteers |
2010-12-01 |
|
| E5555-J081-207 | P2 |
Completed |
Acute Coronary Syndrome |
2009-09-01 |
|
| 2006-000296-15 | P2 |
Completed |
Coronary Artery Disease |
2009-06-09 |